CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis
-The study demonstrated seladelpar to be efficacious, safe and well-tolerated 78.2% of patients on seladelpar 10 mg versus 12.5% on placebo achieved the primary composite outcome after only 3 months (p<0.0001)
-27.3% of patients on seladelpar 10 mg versus zero on placebo normalized ALP by 3 months (p<0.0001)
-Statistically significant improvement in pruritus (p<0.05) for patients with moderate-to-severe itch demonstrated for seladelpar 10 mg versus placebo
-Strongly supports re-initiation of Phase 3 study to confirm the potential of seladelpar to be a best-in-class treatment for PBC
CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020